01 — Why AMRlytics exists
The problem isn't the data. It's the usability.
I'm Ahmad Junaid — a microbiologist by training, not a software engineer. I built AMRlytics because antimicrobial resistance (AMR) is one of the defining global health threats of our time, yet much of the data needed to understand it remains difficult to access, fragmented, and impractical to use.
The world already produces high-quality AMR surveillance data. WHO publishes GLASS reports. ECDC maintains EARS-Net. CDC and national agencies release regional antibiograms and resistance reports. The problem is not the absence of data — it is usability.
Today, answering a straightforward question such as:
can require downloading multiple files, navigating complex spreadsheets, searching PDFs, or querying dashboards one variable at a time.
AMRlytics was built to close that gap — transforming scattered surveillance data into something searchable, interpretable, and useful.
02 — My background
From the lab bench to the platform.
I completed a BS (Hons) in Applied Microbiology in Pakistan, where one of the most influential parts of my training was One Health — the concept that human, animal, and environmental health are interconnected. AMR is one of the clearest examples of this reality.
During the height of the COVID-19 pandemic in 2020, I worked in a BSL-3 containment laboratory, processing diagnostic patient specimens. That experience showed me how valuable timely microbiological data can be — and how often critical information fails to reach the people who need it most.
I later moved to the United Kingdom to complete an MSc in Microbiology with Advanced Practice at Teesside University, where I further developed my laboratory expertise and deepened my interest in resistance mechanisms and translational microbiology.
The technical side of AMRlytics — Python, analytics pipelines, forecasting systems, and dashboard development — was self-taught while building this platform.
The microbiology is the foundation.
The code is the tool.
03 — The problem AMRlytics solves
Open data isn't always usable data.
Raw surveillance data is often functionally inaccessible to the people who need it most.
- WHO datasets may contain multiple summary layers before country-level data appears
- ECDC tools often require one pathogen–antibiotic query at a time
- CDC and national reports are frequently distributed as static PDFs
- Formats differ widely across institutions and countries
The result is that microbiologists, researchers, pharmacists, and clinicians often spend hours manually assembling insights from data that is already public.
AMRlytics converts that burden into a single usable platform.
04 — What AMRlytics does
From surveillance data to actionable intelligence.
AMRlytics integrates surveillance data from WHO GLASS and ECDC EARS-Net (with additional regional sources in development) into one unified intelligence platform.
Users can:
- Track resistance trends across countries, pathogens, and antibiotics
- Compare nations against WHO regions and global baselines
- Detect critical resistance alerts and rapid accelerations
- Benchmark against the WHO Bacterial Priority Pathogens List 2024
- Explore historical trajectory peers
- Forecast future resistance trends using transparent time-series models with confidence intervals
Every feature is designed for practical use by microbiologists, public health professionals, researchers, and stewardship teams.
05 — Scientific approach
Methodologically transparent.
AMRlytics is built with methodological transparency. Interpretations are informed by established frameworks such as:
- WHO AWaRe Classification
- WHO GLASS surveillance principles
- EUCAST standards
- IDSA guidance
- Empiric therapy success thresholds
- Published epidemiological forecasting methods
Where uncertainty exists, it is shown explicitly.
06 — Research and ongoing work
A citable scientific resource.
A methods preprint describing the AMRlytics platform — including data harmonisation, forecasting methodology, and alert classification logic — is currently in preparation for submission to medRxiv.
The goal is to make AMRlytics not only a practical tool, but also a citable scientific resource for future AMR research.
07 — What AMRlytics is not
A surveillance tool, not a clinical one.
AMRlytics is not a clinical decision support system and does not provide medical advice.
Resistance percentages, alerts, and forecasts are population-level surveillance signals — not prescribing recommendations.
Treatment decisions for individual patients must always rely on local antibiograms, susceptibility testing, clinical judgement, current treatment guidelines, and patient-specific factors.
AMRlytics provides the intelligence layer. Clinicians provide the patient care.
Get in touch.
If you are a microbiologist, clinician, pharmacist, researcher, public health professional, or work in pharma R&D — and believe AMRlytics could support your work — I'd be glad to hear from you. Pilot access is currently free, and early feedback is shaping the future of the platform.
📩 hello@amrlytics.ai